Centre for Youth Bipolar Disorder, Sunnybrook Health Sciences Centre, Toronto, Canada.
Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Canada.
Bipolar Disord. 2017 Nov;19(7):524-543. doi: 10.1111/bdi.12556. Epub 2017 Sep 25.
Over the past two decades, there has been tremendous growth in research regarding bipolar disorder (BD) among children and adolescents (ie, pediatric BD [PBD]). The primary purpose of this article is to distill the extant literature, dispel myths or exaggerated assertions in the field, and disseminate clinically relevant findings.
An international group of experts completed a selective review of the literature, emphasizing areas of consensus, identifying limitations and gaps in the literature, and highlighting future directions to mitigate these gaps.
Substantial, and increasingly international, research has accumulated regarding the phenomenology, differential diagnosis, course, treatment, and neurobiology of PBD. Prior division around the role of irritability and of screening tools in diagnosis has largely abated. Gold-standard pharmacologic trials inform treatment of manic/mixed episodes, whereas fewer data address bipolar depression and maintenance/continuation treatment. Adjunctive psychosocial treatment provides a forum for psychoeducation and targets primarily depressive symptoms. Numerous neurocognitive and neuroimaging studies, and increasing peripheral biomarker studies, largely converge with prior findings from adults with BD.
As data have accumulated and controversy has dissipated, the field has moved past existential questions about PBD toward defining and pursuing pressing clinical and scientific priorities that remain. The overall body of evidence supports the position that perceptions about marked international (US vs elsewhere) and developmental (pediatric vs adult) differences have been overstated, although additional research on these topics is warranted. Traction toward improved outcomes will be supported by continued emphasis on pathophysiology and novel therapeutics.
在过去的二十年中,儿童和青少年(即儿科双相情感障碍 [PBD])的双相情感障碍(BD)研究取得了巨大的发展。本文的主要目的是梳理现有文献,消除该领域的神话或夸大的说法,并传播临床相关的发现。
一组国际专家对文献进行了选择性回顾,强调了共识领域,确定了文献中的局限性和差距,并强调了未来的方向以减轻这些差距。
关于 PBD 的现象学、鉴别诊断、病程、治疗和神经生物学,已经积累了大量且日益国际化的研究。围绕易激惹和筛查工具在诊断中的作用的先前分歧已基本消除。金标准药理学试验为躁狂/混合发作的治疗提供了信息,而关于双相抑郁和维持/持续治疗的数据较少。辅助心理社会治疗提供了一个进行心理教育的平台,并主要针对抑郁症状。许多神经认知和神经影像学研究以及越来越多的外周生物标志物研究,与成人 BD 的先前发现基本一致。
随着数据的积累和争议的消散,该领域已经超越了关于 PBD 的存在性问题,转而定义和追求仍然存在的紧迫临床和科学优先事项。总体证据支持这样的观点,即对明显的国际(美国与其他地方)和发展(儿科与成人)差异的看法被夸大了,尽管这些主题还需要更多的研究。对改善结果的关注将得到对病理生理学和新疗法的持续强调的支持。